Both strategies showed a consistent reduction on dengue cases (40%) and dengue-related mortality (43%) compared to no vaccination.
Model Design & Inputs
• An age-structured and serotypespecific deterministic compartmental model which incorporates seasonality, hostvector interactions and 4 dengue virus serotypes immunological interactions was adopted 5 .
• The model was calibrated and validated with Malaysia specific epidemiological data and vaccine efficacy data from phase-III efficacy studies 6 .
• Two vaccination strategies (Table1), were simulated to evaluate the vaccine costeffectiveness.
• Malaysia is currently experiencing the most serious dengue epidemic in its history, with the number of dengue cases 5-7 times higher than the median between 2011-2015 1 .
• On April 15 th 2016, WHO-SAGE on immunization recommended the use of dengue vaccine in countries with high endemicity 2 .
• The first dengue vaccine, Dengvaxia® by Sanofi Pasteur, has been registered in 4 countries.
• With the rapid advancement of dengue vaccine development and projected availability by this year, a Malaysia-specific economic evaluation of dengue vaccine is needed urgently to inform decision makers on the available options for controlling and preventing dengue disease with vaccines.
1. To assess the potential health and economic impact of a 3-dose tetravalent dengue vaccine in Malaysia under different vaccination strategies.
2. To determine the cost-effective threshold price of the dengue vaccine for different vaccination strategies. 
METHODS

Model parameters
Analysis Perspective
• Malaysia public provider.
Time Horizon
• 10 years (2016 -2025) Outcomes / Impacts
• Dengue cases, dengue-related mortality, years-of-life lost (YLL), disability-adjustedlife-year (DALY), dengue treatment cost, and highly cost-effective threshold price (<1x Malaysia GDP per capita). All costs were expressed in 2013 US$.
Sensitivity Analyses
• Probabilistic sensitivity analysis (PSA) was performed by 1,000 Monte Carlo sampling from the joint distribution of plausible ranges of values on dengue treatment cost per case (±20%), vaccine administration cost (±20%), vaccine coverage (90-100%), vaccine wastage (±10%), vaccine protection duration (5-30 years), annual endemicity (1-1000), vaccine efficacy (1-100), and relative efficacy against infection (0-1).
• One-way deterministic sensitivity analysis (DSA) was performed on the highly cost-effective threshold price for the following parameter uncertainties: discount rate (0-5%), vaccine protection duration (5-30 years), model time horizon (5-30 years), catch-up vaccine coverage (±30%), hospitalized underreporting factor (1.0-2.45), ambulatory underreporting factor (1.0-10.38), dengue treatment cost per case (±20%), vaccine administration cost (±20%), and vaccine wastage (±10%).
RESULTS OBJECTIVE 1 RESULTS OBJECTIVE 2 CONCLUSIONS
The results of this study were robust to a wide range of sensitivity. Our analysis demonstrated that introducing a dengue vaccination program in Malaysia has the potential to substantially reduce the disease and economic burden (40% and 43% respectively), especially if it is introduced during current dengue epidemic. Nationwide vaccination showed a bigger overall impact compared to targeted hotspot vaccination. Our study suggested that dengue vaccination is a potentially good investment if the purchaser could negotiate a price at or below the highly cost-effective threshold price, i.e. US$ 12.60 for nationwide vaccination and US$ 34.29 for targeted hotspot vaccination. We hope this study would inform the decision makers on the fair vaccine price and that it could be a medium for negotiations between stakeholders when considering the incorporation of the dengue vaccine into the National Immunization Program. The model predicted that both NW and THS vaccination strategies would reduce the total dengue treatment cost and total dengue management cost over 10 years (2016) (2017) (2018) (2019) (2020) (2021) (2022) (2023) (2024) (2025) • The price threshold for NW vaccination strategy (US$ 12.60, 95%CI: US$ 8.11 -18.70) is found to be lower than the THS vaccination strategy (US$ 34.29, 95%CI: US$ 23.60 -48.83).
• At a price of US$ 10.00, the THS vaccination is 80% highly costeffective.
• At a price of US$ 25.00, the NW vaccination is 95% highly costeffective. The threshold price from both vaccination strategies were most sensitive to the ambulatory underreporting factor, vaccine protection duration and hospitalized underreporting factor. It is least sensitive to the vaccine administration cost and vaccine coverage for catch-up cohort. Contact: huiyeeyeo@yahoo.com
